InDevR’s Research & Development team is committed to developing innovative, cutting edge instrumentation and assays. Here are the future solutions we currently have In The Works…
InDevR is developing a new, multiplexed influenza diagnostic (FluChip-8G™) with the goal of bringing a high information content influenza diagnostic closer to patients. The assay is based on simultaneous amplification of 8 genes followed by hybridization to a microarray with sequence specific targets, automated image analysis and automated results interpretation by a Digital Neural Network. Multiplexed analysis of these 8 genes within a 4 hour assay provides “deep genotyping” in a straightforward, cost effective format. Based on early pre-clinical assessment, the assay accurately identifies virus type and subtype, including B lineage (Yamagata or Victoria), and antiviral susceptibility. The assay is also designed to differentiate species of origin, geographic region of origin, and pathogenicity.
Once cleared by the U.S. Food and Drug Administration, FluChip-8G will enhance clinical diagnosis of influenza in hospitals, urgent care facilities, and clinical laboratories by enabling physicians to rapidly distinguish between seasonal strains and potential pandemic non-seasonal strains of the influenza virus, such as H5N1 or H7N9.
“The FluChip-8G system will provide an unprecedented level of information about viruses detected in human clinical specimens, without the need for virus isolation. This information will allow physicians to make better informed decisions about treatment options for their patients,” said Dr. Kathy Rowlen, InDevR’s CEO.
Initial development was supported through the NIAID’s SBIR program. Product development is now supported by BARDA (see press release).
Please contact us if you would like more information.
Automated Hemagglutination Analyzer
Hemagglutination and hemagglutination inhibition assays are widely used to characterize viruses and related antibodies. Both of these assays rely on manual interpretation which can lead to error in the measurement. In response to this issue, InDevR is developing an analyzer to automate results interpretation and provide a more accurate and precise measurement. This project is funded by NIH SBIR 2-year Phase 1 grant sponsored by the National Institute of Allergy and Infectious Diseases.
Watch this page for more information about what’s coming from InDevR.